Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Biochem Pharmacol. 2015 Jul 29;97(4):566–575. doi: 10.1016/j.bcp.2015.07.030

Fig. 8.

Fig. 8

Effect of various CNS drugs (2 mg/kg, s.c.) on accumulation of [18F]ASEM in CD-1 mouse brain regions 90 min after injection of tracer expressed as %ID/g tissue. Abbreviations: Coll = superior and inferior colliculus; Hipp = hippocampus; Ctx = cortex; CB = cerebellum; REST = rest of brain. Data are mean ± SD (n=3). *P < 0.01, significantly different from controls. Columns that do not include the asterisk are insignificantly different from controls (P > 0.01) (ANOVA, single-factor analysis). The graph demonstrates that unlike the positive control (SSR180711) all non-α7-nAChR CNS drugs do not have an effect on the cerebral uptake of [18F]ASEM that is α7-nAChR selective in vivo. Drugs: SSR180711 – selective a7-nAChR partial agonist; Ondansetron - selective 5-HT3 antagonist; SCH23390 -D1- and D5-antagonist and 5- HT1C/2C agonist; Ketanserin - 5-HT2/5-HT2C antagonist; Naltrindole - Selective δ-opioid antagonist; Cytisine – α4β2-nAChR agonist [48].